Dupixent (dupilumab) works by blocking a specific receptor on cells throughout your body that drives the type of inflammation responsible for eczema. Unlike older treatments that broadly suppress the immune system, Dupixent targets just two signaling molecules, called IL-4 and IL-13, that play a central role in the overactive immune response behind moderate-to-severe atopic dermatitis.
The Inflammation Behind Eczema
Eczema isn’t just a skin problem on the surface. It’s fueled by an immune system that overreacts to triggers, producing too much of two chemical messengers: IL-4 and IL-13. These proteins are part of what scientists call “Type 2 inflammation,” a specific branch of the immune response that normally fights parasites but, in eczema, misfires against your own skin.
IL-4 and IL-13 cause a cascade of problems. They weaken the skin barrier, making it easier for irritants and allergens to penetrate. They trigger intense itching. They recruit inflammatory cells that cause redness and swelling. And they keep the cycle going by telling more immune cells to produce even more IL-4 and IL-13. The result is the persistent, relapsing pattern that makes eczema so frustrating to live with.
How Dupixent Interrupts the Cycle
Dupixent is a monoclonal antibody, essentially a lab-made protein designed to latch onto one very specific target. It binds to a receptor subunit called IL-4Rα, which is a shared component of both the IL-4 and IL-13 receptor complexes on cells. By attaching to IL-4Rα, Dupixent physically blocks IL-4 from docking with its receptor. This single action shuts down signaling from both molecules at once, because IL-4Rα is required for both pathways to activate.
These receptors exist on two types of cells. Type I receptors sit on immune cells like mast cells, eosinophils, and certain white blood cells. Type II receptors are found on structural cells, including the skin cells (keratinocytes) and connective tissue cells that make up your skin barrier. Dupixent blocks IL-4Rα on both receptor types, which means it calms the overactive immune cells and helps restore normal skin barrier function at the same time.
This targeted approach is what sets Dupixent apart from broad immunosuppressants. Because it only interferes with Type 2 inflammation rather than suppressing the entire immune system, it carries a lower risk of the serious infections and organ damage associated with older systemic treatments.
How Quickly It Works
Itch relief is typically the first improvement patients notice. In clinical trials, a meaningful reduction in itch scores appeared by week 12, with response rates continuing to climb through week 24. In one study, 60% of patients on Dupixent achieved at least a 4-point drop in their itch severity score by week 24, compared to 18.4% on placebo. Clinical experts note that more than 12 weeks is often needed to see the full effects, so patience in the early weeks matters.
Visible skin clearance follows a similar pattern. Across pooled clinical trial data involving over 2,600 patients, Dupixent improved the rate of achieving 75% skin clearance (a benchmark called EASI-75) by 37 percentage points compared to placebo. In children aged 6 to 11 with severe eczema using Dupixent alongside a medium-potency topical steroid, roughly 67 to 70% reached that 75% clearance threshold at 16 weeks, compared to about 27% with the steroid alone.
Who Can Use It
Dupixent is FDA-approved for patients aged 6 months and older with moderate-to-severe atopic dermatitis whose eczema isn’t adequately controlled with prescription topical treatments, or when those topical therapies aren’t advisable. In practice, this means it’s reserved for people who’ve tried topical steroids or other prescription creams and still have significant disease.
The injection is given under the skin. Adults start with a loading dose of two 300 mg injections, then continue with one 300 mg injection every two weeks. For children and teens aged 6 to 17, the dose and frequency depend on body weight. Kids under 30 kg receive 300 mg every four weeks after their loading dose. Those between 30 and 60 kg get 200 mg every two weeks, and those 60 kg and above follow the same schedule as adults. Most patients or caregivers learn to give the injections at home after initial guidance.
Using Dupixent With Topical Steroids
Dupixent is often prescribed alongside topical corticosteroids rather than as a standalone treatment, and clinical trials reflect this real-world approach. In the pediatric trial of children aged 6 to 11, all groups used a medium-potency topical steroid in addition to their injections. The combination produced significantly better outcomes than the steroid alone across every measure: skin clearance, itch reduction, and quality of life. This means you’ll likely continue using your topical treatments, potentially at a reduced frequency, rather than abandoning them entirely when you start Dupixent.
Common Side Effects
The most notable side effect is eye-related inflammation, particularly conjunctivitis. This appears to be a direct consequence of blocking IL-4 signaling. IL-4 plays a role in maintaining the oil-producing glands in your eyelids, so when Dupixent suppresses that signal, those glands can become less functional, leading to dry, irritated, or pink eyes. Mild cases can often be managed with lubricating eye drops, though moderate or severe eye symptoms may need treatment from an ophthalmologist.
Injection site reactions, such as redness, swelling, or mild pain where the needle goes in, are also reported more frequently with Dupixent than placebo. These are generally mild and tend to improve over time as your body adjusts.
What’s reassuring in the clinical data is that serious adverse events were actually less common in patients taking Dupixent than in those on placebo. Only 3.9% of Dupixent-treated patients experienced a severe side effect, compared to 8.3% on placebo. Much of that difference was driven by eczema flares themselves, which were far more common in untreated patients.
Long-Term Effectiveness
Open-label extension studies tracking patients for up to three years in adults and one year in children and adolescents show that the improvements seen in the initial trials hold up over time. Adults using Dupixent with topical corticosteroids maintained rapid and sustained improvement across all body regions over 52 weeks. Lab safety findings from these extension studies in both adolescents and adults remained consistent with the shorter trial data, with no new safety signals emerging over longer use. For a condition as chronic as eczema, this durability is one of the more significant findings, since many older treatments lose effectiveness or become unsafe with prolonged use.